Othmar Moser, Alexander Müller, Felix Aberer, Faisal Aziz, Harald Kojzar, Caren Sourij, Anna Obermayer, Farah Abbas, Philipp Birnbaumer, Jacqueline Lenz, Ines Mursic, Christoph Sternad, Lukas Hönger, Haris Ziko, Peter N Pferschy, Norbert Tripolt, Harald Sourij
Aims: In the ULTRAFLEXI-1 study, we compared basal insulin Glargine 300 U/mL (IGlar U300) and insulin Degludec 100 U/mL (IDeg U100) for time below range <70 mg/dL (TBR<70 ; 3.9 mmol/L) in two different doses (100% and 75% of the regular dose) when used around spontaneous exercise sessions in adults with type 1 diabetes. Methods: A randomized, single-center, four-period, cross-over trial was performed and in each of the four 2-weeks-periods, participants attended six spontaneous 60 min moderate-intensity evening cycle ergometer exercise sessions...
March 2023: Diabetes Technology & Therapeutics